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Radioiodination of BODIPY and its 
application to a nuclear and optical 
dual functional labeling agent for 
proteins and peptides
Masahiro Ono, Hiroyuki Watanabe, Yuki Ikehata, Ning Ding, Masashi Yoshimura, Kohei Sano 
& Hideo Saji
In molecular imaging research, the development of multimodal imaging probes has recently attracted 
much attention. In the present study, we prepared radioiodinated BODIPY and applied it as a nuclear 
and optical dual functional labeling agent for proteins and peptides. We designed and synthesized [125I]
BODIPY with a N-hydroxysuccinimide (NHS) ester, and evaluated its utility as a nuclear and fluorescent 
dual labeling agent for proteins and peptides. In the radioiodination reaction of BODIPY-NHS with [125I]
NaI, [125I]BODIPY-NHS was obtained at a 48% radiochemical yield. When we carried out the conjugation 
reaction of [125I]BODIPY-NHS with bovine serum albumin (BSA) and RGD (Arg-Gly-Asp) peptide as 
a model protein and peptide, respectively, [125I]BODIPY-BSA and [125I]BODIPY-RGD peptide were 
successfully prepared at 98 and 82% radiochemical yields, respectively. Furthermore, we prepared 
[123I]BODIPY-trastuzumab by this conjugation reaction and successfully applied it to single photon 
emission computed tomography (SPECT) imaging studies using tumor-bearing mice, suggesting that 
radioiodinated BODIPY-NHS serves as a dual functional labeling agent for proteins and peptides. 
Since iodine has various radioisotopes that can be used for SPECT and positron emission tomography 
(PET) imaging, biological research, and radiotherapy, the radioiodinated BODIPY may be extensively 
applicable from basic to clinical research.
The in vivo quantitative detection of the biodistribution of biologically active proteins and peptides plays an 
important role in a wide range of research in life science. In such research, the in vivo pharmacokinetics of pro-
teins and peptides labeled with radionuclides or fluorescent dye are determined using a nuclear or optical imaging 
technique. Nuclear imaging techniques including positron emission tomography (PET) and single photon emis-
sion computed tomography (SPECT) constitute some of the most common clinical imaging modalities because 
they can offer a variety of important information on the in vivo biodistribution of radiolabeled, biologically active 
proteins and peptides1, 2. In contrast, optical imaging with fluorescent probes has become a versatile modality that 
has been used for clinical intraoperative tumor detection and in vivo imaging studies using small animals3. Since 
both nuclear and optical imaging methods have distinctive characteristics appropriate for clinical application, a 
dual modality imaging system that combines these two imaging techniques may noninvasively provide comple-
mentary information for the diagnosis of various diseases. Many dual imaging probes that can be applied to such 
nuclear and optical dual modality imaging have been reported4–11. Among them, Li et al. recently investigated 
the radiofluorination of BODIPY, which is one of the well-known fluorescent dyes (Fig. 1)12. They reported that 
one of two fluorine atoms in the boron center of BODIPY can be used for radiofluorination, and applied [18F]
BODIPY as a dual modality imaging agent for the first time (Fig. 1). [18F]BODIPY is an attractive dual imaging 
agent because it can be integrated with positron emission tomography and the optical properties of the imaging 
agent in the same molecule. Several dual imaging probes with [18F]BODIPY including [18F]BODIPY®FL-RGD 
(Fig. 1) have been reported13–15. However, the relatively short half-life of 18F (t1/2 = 110 min) makes the use of [18F]
BODIPY limited. In particular, it may not be appropriate to determine the in vivo pharmacokinetics of proteins 
such as antibodies using this approach with [18F]BODIPY conjugates because, in general, the half-life of such 
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proteins in the blood does not match that of 18F. Therefore, to determine the pharmacokinetics of proteins conju-
gated with [18F]BODIPY, it is necessary to develop new agents that can label the proteins with other radionuclides 
with a longer half-life than 18F.
In numerous studies regarding the chemistry of BODIPY16, we found that it is possible to introduce iodine 
into pyrrole rings of the BODIPY scaffold17, 18. Since iodine has several radionuclides, including 123I (t1/2 = 13.2 h, 
γ), 124I (t1/2 = 4.18 d, β+), 125I (t1/2 = 59.4 d, Auger e−), and 131I (t1/2 = 8.02 d, β−), it can be applied to broad research 
from basic research to diagnostic imaging and clinical radiotherapy in consideration of their half-life and char-
acteristics of radiation19. Therefore, we considered that radioiodinated BODIPY can be used to develop a new 
method for the dual functional labeling of biologically active peptides and proteins.
In the present study, we synthesized radioiodinated BODIPY ([123/125I]BODIPY) and applied it as a nuclear 
and optical dual functional labeling agent. We selected bovine serum albumin (BSA), RGD peptide, and trastu-
zumab as a model protein, peptide, and biologically active protein, respectively, to validate the basic concept for 
the development of new dual functional probes based on the radioiodinated BODIPY, and evaluated the feasibil-
ity of using [123/125I]BODIPY as a dual functional labeling agent for peptides and proteins.
Results and Discussion
Synthesis and characterization of 125I-labeled BODIPY ([125I]2). We carried out a radioiodination 
reaction according to the synthetic route shown in Fig. 2. The BODIPY scaffold (1) was radioiodinated with [125I]
NaI in the presence of hydrogen peroxide as the oxidant. The radiochemical identity of 125I-labeled BODIPY 
([125I]2) was verified by the HPLC profile of nonradioactive iodo-BODIPY (2), which was synthesized according 
to a method reported previously (Fig. 3)17. We efficiently prepared [125I]2 at a radiochemical yield of 75.1% with 
a radiochemical purity of >99% after purification by HPLC. This efficiency of radiolabeling was similar to that 
obtained with the conventional radioiodination including electrophilic reactions with activated aromatic groups, 
and iodo-demetalation of aryls and alkyenes, using organotin or silicon precursors19, 20. The new radioiodination 
reaction of BODIPY may be applicable for a variety of BODIPY derivatives.
Next, in order to determine the in vitro stability of [125I]2, we incubated [125I]2 in murine plasma for 24 h at 
37 °C. When we analyzed it with HPLC after 24-h incubation of [125I]2 in murine, the radioactivity peak after 24-h 
incubation had not changed markedly in comparison with that before incubation (Fig. 4). This result suggests 
that [125I]2 shows high stability in murine plasma, indicating that the in vivo biodistribution of [125I]2 should be 
further evaluated.
Then, we evaluated the biodistribution of radioactivity after the intravenous injection of [125I]2 into normal 
mice (Fig. 5). The radioactivity of [125I]2 after injection into mice displayed a typical biodistribution pattern for 
low-molecular-weight lipophilic compounds. In other words, as [125I]2 was cleared from the blood, approximately 
Figure 1. Chemical structures of BODIPY, [18F]BODIPY, and [18F]BODIPY®FL-RGD.
Figure 2. Radioiodination reaction of BODIPY.
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30%ID/g of [125I]2 accumulated in the liver at 2 min postinjection. High radioactivity accumulation was also 
observed in the heart (12%ID/g) and lungs (25%ID/g) at 2 min postinjection. Thereafter, the radioactivity 
observed in the liver, heart, and lungs was gradually excreted into the intestine, and the radioactivity in the intes-
tine reached 20%ID/g at 60 min postinjection. No marked radioactivity accumulation in the thyroid or stomach 
was observed, suggesting that [125I]2 showed high stability against the deiodination reaction in vivo in addition to 
Figure 3. HPLC profiles of 2 (absorbance at 254 nm, A) and [125I]2 (radioactivity, B).
Figure 4. HPLC profiles of [125I]2 before (A) and after (B) incubation for 24 h.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 3337  | DOI:10.1038/s41598-017-03419-z
high in vitro stability in plasma. This also suggests that [125I]2 may provide stable in vivo nuclear and optical dual 
functional probes when applied for the labeling of various proteins and peptides.
Synthesis of 125I-labeled BODIPY with an active ester ([125I]4) and conjugation reaction of [125I]4 
with protein and peptide. Next, we designed and synthesized [125I]4 with a N-hydroxysuccinimide (NHS) 
ester as a conjugation site with proteins and peptides. The nonradioactive 4 was synthesized from known com-
pound 3 using N-iodosuccinimide (NIS) at a yield of 54.1% (Fig. 6). Compound 4 had maximum excitation and 
emission wavelengths of 523 and 541 nm, respectively, and the extinction coefficient (M−1cm−1) and quantum 
yield (%) of 4 were 90,600 and 11.0, respectively. Furthermore, [125I]4 was synthesized by the radioiodination 
of compound 3 with [125I]NaI in the presence of N-chlorosuccinimde (NCS) and 10% acetic acid in methanol 
(Fig. 7). After purification with HPLC by the co-injection of nonradioactive compound 3, [125I]4 was successfully 
obtained at a radiochemical yield of 47.8% with a radiochemical purity of >99% (Fig. 8). We also attempted radi-
oiodination with a different method using hydrogen peroxide as the oxidant, similarly to the method used in the 
Figure 5. Biodistribution of radioactivity after injection of [125I]2 into mice (*expressed as %Dose).
Figure 6. Iodination reaction of 3 (BODIPY-NHS).
Figure 7. Radioiodination reaction of 3 (BODIPY-NHS).
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radioiodination of [125I]2. However, we could not obtain [125I]4 at high yields in this reaction, probably because 
the hydrolysis of the NHS ester of compound 3 occurred due to a reaction with water. Therefore, we changed to 
the condition of the radioiodination reaction to avoid using water as a solvent. Although we used methanol as a 
solvent in this reaction, no marked methyl esterification was observed.
Next, we used [125I]4 for a conjugation reaction with proteins and peptides. In the present study, we firstly 
selected BSA and RGD peptide as a model protein and peptide, respectively, for dual labeling with [125I]4. After the 
conjugation reaction of [125I]4 with BSA at room temperature for 80 min, we purified [125I]4-BSA with size-exclusion 
chromatography. The radioactivity peak derived from [125I]4-BSA corresponded to that of absorbance at 280 nm, 
indicating that the conjugation of [125I]4 with BSA should be successfully achieved (Fig. 9). Furthermore, when 
we determined the fluorescence at an emission of 520 nm, the fluorescent peak was detected at a similar elution 
volume to that of absorbance and radioactivity (Fig. 9). To determine whether [125I]4 binds to BSA via the covalent 
bonds of the NHS ester of [125I]4, we analyzed [125I]4-BSA by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) (Fig. 10). The reaction mixture of [125I]2 and BSA was also analyzed by SDS-PAGE as a 
control experiment (lane 3 in Fig. 10). As a result, most [125I]4-BSA was detected as a monomer of BSA together 
with a small amount of BSA dimer, and no marked radioactivity of [125I]4-BSA was found in a region where 
low-molecular-weight compounds were observed (Fig. 10). This means that the bonds between [125I]4 and BSA 
should be mainly formed by the covalent bonding of the NHS ester of [125I]4 with the amino groups of BSA.
Next, we carried out the conjugation reaction of [125I]4 with RGD peptide. Many radiolabeled and fluores-
cent imaging probes based on RGD peptide have been studied for the in vivo imaging of tumors21. Therefore, 
we selected the RGD peptide as a model peptide in this study to show the basic principle for dual labeling with 
[125I]4. We synthesized 4-RGD and used it as a nonradioactive standard in the HPLC analysis. The retention time 
of the radioactivity peak was identical to that of the absorbance of 4-RGD, suggesting that [125I]4 was successfully 
conjugated to RGD peptide similarly to the conjugation reaction of [125I]2 with BSA (Fig. 11). The results for the 
conjugation reaction of [125I]4 with BSA and RGD peptide also support the feasibility of nuclear and optical dual 
functional labeling of various other biologically active proteins and peptides including antibodies, antibody frag-
ments, and other carriers including liposomes, micelles, and polymer conjugates22, 23.
Then, we applied this conjugation reaction to the labeling of trastuzumab with [125I]4 as one of the examples 
of biologically active proteins and peptides. Trastuzumab is an antibody against human epidermal growth factor 
receptor 2 (HER2) that is overexpressed in several cancers, and commonly used as a carrier protein of radioi-
sotopes and fluorescence dyes for the in vivo imaging of cancers24, 25. According to the similar method used for 
the conjugation reaction of BSA, we reacted [125I]4 with trastuzumab, and purified the reaction mixture with 
size-exclusion chromatography. As shown in Fig. 12, the elution volume where the radioactivity peak was detected 
corresponded to that of UV absorption where intact trastuzumab was eluted, indicating that trastuzumab was 
labeled with [125I]4. We also analyzed [125I]4-trastuzumab by SDS-PAGE. The radioactivity of [125I]4-trastuzumab 
was detected in a region where the intact trastuzumab was detected while no marked radioactivity was found in 
a region where low-molecular-weight compounds were detected (Fig. 13). This suggests that the NHS ester of 
[125I]4 may bind to the amino groups of trastuzumab via covalent bonds, similarly to [125I]4-BSA.
Figure 8. HPLC profiles of 4 (absorbance at 254 nm, A) and [125I]4 (radioactivity, B).
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Figure 9. Size-exclusion chromatography of [125I]4-BSA by the detection of absorbance (280 nm) (A), 
radioactivity (B), and fluorescence (520 nm) (C).
Figure 10. Analysis of [125I]4-BSA by SDS-PAGE. Left and right panels show CBB staining (A) and 
autoradiography (B), respectively. BSA (8 ng) only (lane 1, CBB staining), [125I]4-BSA (8 ng) (lane 2, CBB 
staining and autoradiography), and the reaction mixture of [125I]2 and BSA (8 ng) (lane 3, CBB staining and 
autoradiography) were subjected to SDS-PAGE, respectively. Lane M shows molecular weight markers. Images 
were cropped to remove extraneous areas.
www.nature.com/scientificreports/
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Next, we prepared [123I]4-trastuzumab and conducted SPECT imaging studies in HER2-positive N87 
tumor-bearing mice. As a result, tumors in the mice were clearly detected by SPECT imaging after the injection 
of [123I]4-trastuzumab (Figs. 14 and S1), suggesting that123 4 may function as a radiolabeling agent without any 
loss of biological activity of an antibody. Since no marked radioactivity accumulation was observed in the thy-
roid (Fig. S1B), [123I]4 shows high stability against in vivo deiodination reactions even after conjugation with an 
antibody, suggesting that radioiodine may stably bind to the BODIPY scaffold in vivo. In the present study, we 
did not perform in vivo fluorescence imaging due to the relatively low excitation and emission wavelengths of 
BODIPY 4 that are inadequate for in vivo fluorescent imaging. However, the successful SPECT imaging with 
Figure 11. HPLC profiles of 4-RGD (absorbance at 218 nm, A) and [125I]4-RGD (radioactivity, B).
Figure 12. Size-exclusion chromatography of [125I]4-trastuzumab by the detection of absorbance (280 nm) (A) 
and radioactivity (B).
www.nature.com/scientificreports/
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[123I]4-trastuzumab suggests the feasibility of RI/fluorescence dual imaging, in principle, by replacing it with the 
new BODIPY derivative with longer excitation and emission wavelengths effective for in vivo imaging.
Conclusions
In this study, for the first time, we revealed that radioiodinated BODIPY can function as a new agent useful for 
the nuclear and optical dual functional labeling of various biologically active proteins and peptides. Since iodine 
has several radioisotopes with various features suitable for use in fields from basic research to clinical applica-
tion, proteins and peptides labeled with radioiodinated BODIPY may be applied extensively for not only clinical 
diagnosis by SPECT/fluorescence dual imaging with [123I]BODIPY conjugates but also radiotherapy with [131I]
BODIPY conjugates.
Experimental
General. All reagents in this study were commercial products used without further purification. Sodium [125I]
iodide ([125I]NaI) and [123I]NaI were purchased from PerkinElmer and FUJIFILM RI Pharma Co., Ltd., respec-
tively. Smart Flash EPCLC W-Prep 2XY (Yamazen Corporation) was used for silica gel chromatography. 1H NMR 
was recorded on a JNM-ECS400 (JEOL) with tetramethylsilane (TMS) as an internal standard. Coupling con-
stants are reported in Hertz (Hz). Multiplicity was defined as singlet (s), doublet (d), triplet (t), multiplet (m), and 
Figure 13. Analysis of [125I]4-trastuzumab by SDS-PAGE. Left and right panels show CBB staining (A) and 
autoradiography (B), respectively. [125I]4-trastuzumab (2.5 ng) was subjected to SDS-PAGE (Lane 1). Lane M 
shows molecular weight markers. Images were cropped to remove extraneous areas.
Figure 14. SPECT/CT images of an N87 tumor-bearing mouse at 8 h (A and C) and 24 h (B and D) after the 
injection of [123I] 4-trastuzumab (A and B: transversal image, C and D: coronal image). The white arrows 
indicate the tumor.
www.nature.com/scientificreports/
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quartet (q). ESI mass spectrometry was conducted with a Shimadzu LCMS-2020. High-resolution mass spec-
trometry (HRMS) was conducted with JMS-700V (JEOL). High-performance liquid chromatography (HPLC) 
was performed with Shimadzu system (an LC-20AD pump with an SPD-20A UV detector, λ = 254 nm) using 
a Cosmosil C18 column (Nacalai Tesque, COSMOSIL 5C18-AR-II 4.6 mm I.D. × 150 mm) and CH3CN/H2O (60: 
40) as the mobile phase at a flow rate of 1.0 mL/min. HER2-expressing human gastric cancer cells (N87) were 
purchased from DS Pharma Biomedical (Osaka, Japan).
Chemistry. Compounds 1, 2, and 3 were synthesized according to the previous procedures reported by Wang 
et al.26, Chen et al.17, and Nepomnyashchii et al.27, respectively.
2-Iodo-8-(4-(N-succinimidoxycarbonyl)phenyl)−1,3,7,9-tetramethyl-BODIPY (4). To a solu-
tion of BODIPY derivative 3 (100.0 mg, 0.21 mmol) in CH2Cl2 (25 mL), N-iodosuccinimide (NIS) (48.4 mg, 
0.21 mmol) in CH2Cl2 (10 mL) was added dropwisely and the reaction mixture was stirred at 0 °C for 30 min. 
After the addition, the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was evapo-
rated under a vacuum. The residue was purified by silica gel chromatography (CHCl3/n-hexane = 10/1) to provide 
68.7 mg of 4 at a yield of 54.1%. 1H NMR (400 MHz, (CDCl3) δ 8.30 (d, J = 8.40 Hz, 2 H), 7.49 (d, J = 8.40 Hz, 2 H), 
6.08 (s, 1 H), 2.96 (s, 4 H), 2.64 (s, 3 H), 2.58 (s, 3 H), 1.38 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 14.8, 15.0, 17.1, 
25.6, 84.8, 122.7, 126.0, 128.9, 130.1, 131.1, 131.4, 138.9, 141.8, 143.0, 144.7, 155.4, 158.6, 161.1, 169.1. HRMS 
(FAB) 591.0625 [M+] (Chemical formula: C24H21BF2IN3O4, calculated m/z value: 591.0638).
RGD peptide conjugated with 4 (4-RGD). 4-RGD was synthesized according to a method reported pre-
viously15. BODIPY derivative 4 (0.89 mg, 1.5 µmol) and c(RGDyK) (0.40 mg, 0.65 µmol, used as RGD) in DMSO 
(50 µL) were mixed and N,N-diisopropylethylamine (5 µL) was added to the mixture. After 3-h incubation, the 
reaction mixture was purified by reversed-phase HPLC. The flow rate was 1 mL/min, with the mobile phase 
starting from 90% solvent A (0.1% TFA in water) and 10% solvent B (0.1%TFA in CH3CN) to 0% solvent A and 
100% solvent B at 20 min. 1H NMR (400 MHz, CD3OD) δ 8.05 (d, J = 8.40 Hz, 2 H), 7.50 (d, J = 8.00 Hz, 2 H), 7.00 
(d, J = 8.40 Hz, 2 H), 6.69 (d, J = 8.80 Hz, 2 H), 6.19 (s, 1 H), 4.65–4.60 (m, 1 H), 4.46–4.44 (m, 1 H), 4.32–4.26 (m, 
2 H), 3.95–3.91 (m, 1 H), 3.49–3.45 (m, 2 H), 3.13–3.12 (m, 1 H), 2.89–2.80 (m, 3 H), 2.62–2.52 (m, 8 H), 1.60–1.49 
(m, 7 H), 1.43–1.42 (m, 7 H), 1.34–1.29 (m, 7 H), 1.11–1.06 (m, 1 H), 0.91–0.88 (m, 2 H). MS (ESI) m/z 1096.7 
[M + H+] (Chemical formula: C47H58BF2IN11O9, calculated m/z value: 1096.3).
Determination of fluorescence parameters. The fluorescence parameters including fluorescence excita-
tion/emission wavelength and intensity were measured by an RF-5300 and RF-1500 fluorescence spectrophotom-
eter (Shimadzu).
Preparation of [125I]2. To a solution of 1 (1 mg/mL, 50 µL EtOH), [125I]NaI (1.3–1.7 MBq), 1 N HCl (50 µL), 
and 3% H2O2 (50 µL) were added. The reaction was allowed to proceed at room temperature for 60 min and 
terminated by the addition of saturated NaHSO3 aq. (100 µL). The reaction mixture was neutralized by adding 
a solution of saturated NaHCO3 aq. (200 µL) and extracted with ethyl acetate. After the organic phase was dried 
by passing through a column filled with anhydrous Na2SO4, the solution was dried with a stream of argon gas. 
[125I]2 was purified by the reversed-phase HPLC on a COSMOSIL 5C18-AR-II column with an isocratic solvent of 
CH3CN/H2O = 4/1 at a flow rate of 1 mL/min.
Preparation of [123/125I]4. BODIPY derivative 3 was dissolved in methanol containing 1% acetic acid 
(0.5 mg/mL, 50 µL). To this solution, N-chlorosuccinimide (NCS) in methanol (0.5 mg/mL, 20 µL) and [123/125I]
NaI (1.5–3.8 MBq or 111 MBq for 125I or 123I labeling, respectively) were added. After the reaction mixture was 
incubated at room temperature for 40 min, saturated NaHSO3 aq. (100 µL) was added to quench the reaction. The 
reaction mixture was neutralized by adding a solution of saturated NaHCO3 aq. (200 µL) and extracted with ethyl 
acetate. After the organic phase was dried by passing through a column filled with anhydrous Na2SO4, the solu-
tion was dried with a stream of argon gas. [123/125I]4 was purified by the reversed-phase HPLC on a COSMOSIL 
5C18-AR-II column with an isocratic solvent of CH3CN/H2O = 3/2 at a flow rate of 1 mL/min.
Conjugation of [125I]4 with BSA. To a solution of bovine serum albumin (BSA) in 50 mM borate buffer 
(pH 8.5) (1.88 mg/mL, 1.0 mL), [125I]4 (185 kBq, 50 µL) was added. The reaction mixture was incubated at 
room temperature for 80 min. Thereafter, a solution of the reaction mixture was fractionated every 0.5 mL by 
size-exclusion chromatography with the PD-10 column eluted with 5% DMF in 50 mM borate buffer (pH 8.5). 
The radioactivity in each fraction was measured, and the fractions that corresponded with the absorbance of BSA 
were calculated as [125I]4-BSA.
Conjugation of [125I]4 with RGD peptide. We prepared RGD peptide-conjugated [125I]4 on the basis of a 
method reported previously15. To a mixture of [125I]4 (0.66 MBq) and c(RGDyK) (0.2 mg) in DMSO (50 µL) was 
added DIPEA (2 µL). After 2-h incubation, the reaction mixture was purified with HPLC to yield [125I]4-RGD at 
an 82.0% radiochemical yield and over 99% radiochemical purity.
Conjugation of [123/125I]4 with trastuzumab. We added [123/125I]4 (185 kBq or 24–30 MBq for 125I or 123I 
labeling, respectively) in DMSO (50 µL) and PBS (pH 8.6, 500 μL) to a solution of trastuzumab in PBS (pH 8.6, 
1 mg/mL, 500 μL). The reaction mixture was incubated at room temperature for 80 min. Thereafter, a solution of 
the reaction mixture was fractionated every 0.5 mL by size-exclusion chromatography with the PD-10 column 
eluted with PBS (pH 8.6). The radioactivity in each fraction was measured, and the fractions that corresponded 
with the absorbance of trastuzumab were calculated as [125I]4-trastuzumab.
www.nature.com/scientificreports/
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SDS PAGE analysis of [125I]4-BSA and [125I]4-trastuzumab. We analyzed [125I]4-BSA and 
[125I]4-trastuzumab with SDS-PAGE with a 10−20 and 5–20% gradient polyacrylamide gel (ATTO) for 
[125I]4-BSA and [125I]4-trastuzumab, respectively. A protein molecular weight marker was used simultaneously. 
After electrophoresis at 20 mA for 60 and 65 min for [125I]4-BSA and [125I]4-trastuzumab, respectively, the gel was 
stained with Coomassie Brilliant Blue (CBB) G-250 (Invitrogen, Simple Blue SafeStain) to determine the molecu-
lar weight of [125I]4-BSA and [125I]4-trastuzumab. Furthermore, the gel was exposed to a BAS imaging plate (Fuji 
Film). Autoradiographic images were obtained using a BAS 5000 scanner system (Fuji film).
In vitro stability of [125I]2 in plasma. [125I]2 (50 µL in a mixed solvent of 90% saline and 10% EtOH, 
0.11–0.22 MBq) was diluted with freshly prepared murine plasma (250 µL). The solution was incubated at 37 °C 
for 24 h. After the addition of acetonitrile (600 µL) and vortexing, the mixture was centrifuged (4 °C, 10,000 g, 
5 min). The supernatant was filtered and the filtrate was analyzed by reversed-phase HPLC using a COSMOSIL 
column (5C18 AR-II) with an isocratic solvent of CH3CN/H2O (4/1) at a flow rate of 1.0 mL/min.
In vivo biodistribution in normal mice. Animal experiments were conducted in accordance with our 
institutional guidelines and approved by Kyoto University. A saline solution (100 μL) containing 0.1% tween 80 
and 10% ethanol of [125I]2 (37 kBq) was injected intravenously into the tails of ddY mice (5 weeks old, male, 5 
animals per each group). The mice were sacrificed at 2, 10, 30, and 60 min postinjection. The organs of interest 
were removed and weighed, and the radioactivity was measured with an automatic γ counter (Wizard 1470, 
PerkinElmer). The results were calculated as the percentage injected dose per gram (%Dose/g) or percentage 
injected dose (%Dose). Values are expressed as the mean ± SD.
SPECT/CT study. N87 (human gastric cancer cell) tumor-bearing mice were prepared as reported pre-
viously28. [123I]4-trastuzumab (2.2–4.1 MBq/ 60–150 μg, 150 μL PBS) was intravenously injected into the N87 
tumor-bearing mice (n = 3). The mice were anesthetized by isoflurane (2–2.5%), and SPECT and CT images were 
obtained using the U-SPECT-II/CT system (MILabs, Utrecht, the Netherlands) with 0.6-mm pinhole collimators 
(SPECT conditions: 60 min × 1 frame; CT conditions: accurate full angle mode in 65 kV/615 μA) at 8 and 24 h 
after injection of [123I]4-trastuzumab. SPECT images were reconstructed using the OSEM method (8 subset, 1 
iteration) with a 0.6-mm Gaussian filter.
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